[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020006013A - Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment. - Google Patents

Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment.

Info

Publication number
MX2020006013A
MX2020006013A MX2020006013A MX2020006013A MX2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A MX 2020006013 A MX2020006013 A MX 2020006013A
Authority
MX
Mexico
Prior art keywords
fragment
increased affinity
receptor
fcrn
variants
Prior art date
Application number
MX2020006013A
Other languages
Spanish (es)
Inventor
Céline Monnet
Philippe Mondon
Harry Meade
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2020006013A publication Critical patent/MX2020006013A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the FcγRI (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a) receptors, relative to that of the parent polypeptide, characterised in that it comprises: (i) the four mutations 334N, 352S, 378V and 397M; and (ii) at least one mutation chosen from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; the numbering being that of the EU index or the Kabat equivalent.
MX2020006013A 2017-12-15 2018-12-14 Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment. MX2020006013A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1762217A FR3075200B1 (en) 2017-12-15 2017-12-15 VARIANTS WITH FC FRAGMENT HAVING INCREASED AFFINITY FOR FCRN AND INCREASED AFFINITY FOR AT LEAST ONE FC FRAGMENT RECEIVER
PCT/EP2018/084970 WO2019115773A1 (en) 2017-12-15 2018-12-14 Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment

Publications (1)

Publication Number Publication Date
MX2020006013A true MX2020006013A (en) 2020-08-17

Family

ID=62816603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006013A MX2020006013A (en) 2017-12-15 2018-12-14 Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment.

Country Status (11)

Country Link
US (1) US20210214434A1 (en)
EP (1) EP3724221A1 (en)
JP (2) JP2021508444A (en)
KR (1) KR20200098512A (en)
CN (2) CN118812703A (en)
AU (1) AU2018382593A1 (en)
BR (1) BR112020012016A2 (en)
CA (1) CA3084602A1 (en)
FR (1) FR3075200B1 (en)
MX (1) MX2020006013A (en)
WO (1) WO2019115773A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101640B1 (en) 2019-10-07 2024-04-12 Lab Francais Du Fractionnement Human monocyte cell line and its use as a cellular model of phagocytosis.
WO2021234655A2 (en) * 2020-05-21 2021-11-25 Cadila Healthcare Limited Fc variant and preparation thereof
KR102341138B1 (en) 2020-05-31 2021-12-21 주식회사 엑소코바이오 Exosomes comprising exosomal membrane protein variant and manufacturing method thereof
KR20220101559A (en) 2021-01-11 2022-07-19 주식회사 엑소코바이오 Exosome comprising overexpressed Fc receptor or its part and manufacturing method thereof
KR20220106696A (en) 2021-01-21 2022-07-29 주식회사 엑소코바이오 Recombinant exosome comprising Fc receptor or its part which can be fused to target protein or peptide and its use
WO2023191766A1 (en) * 2022-03-28 2023-10-05 Intervexion Therapeutics, Llc ANTIBODIES WITH ALTERED FcRn AFFINITY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I1 (en) 1986-04-09 2007-05-16 Genzyme Corp Genetically transformed animals secreting a desired protein in milk
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
JP2008504002A (en) * 2003-11-12 2008-02-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Neonatal Fc receptor (FcRn) binding polypeptide variants, dimeric Fc binding proteins, and methods related thereto
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
FR2957598B1 (en) * 2010-03-17 2015-12-04 Lfb Biotechnologies NOVEL SIGNAL PEPTIDE AND USE THEREOF FOR THE PRODUCTION OF RECOMBINANT PROTEINS
US20170129966A1 (en) * 2014-06-02 2017-05-11 Laboratoire Français Du Fractionnement Et Des Biotechnologies Production of fc fragments
FR3024453B1 (en) * 2014-08-01 2018-06-29 Lab Francais Du Fractionnement PROCESS FOR PRODUCING VARIANTS HAVING FC HAVING ENHANCED SIALYLATION
FR3035879A1 (en) * 2015-05-07 2016-11-11 Lab Francais Du Fractionnement MUTANTS FC WITH MODIFIED FUNCTIONAL ACTIVITY
FR3038517B1 (en) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY
FR3051794A1 (en) * 2016-05-31 2017-12-01 Lab Francais Du Fractionnement ANTIBODIES FOR THE TREATMENT OF CANCERS
FR3053688A1 (en) * 2016-07-06 2018-01-12 Laboratoire Francais Du Fractionnement Et Des Biotechnologies FC MUTANTS WITH IMPROVED FUNCTIONAL ACTIVITY

Also Published As

Publication number Publication date
CN111601821A (en) 2020-08-28
EP3724221A1 (en) 2020-10-21
KR20200098512A (en) 2020-08-20
CA3084602A1 (en) 2019-06-20
JP2021508444A (en) 2021-03-11
FR3075200B1 (en) 2022-12-23
AU2018382593A1 (en) 2020-06-25
US20210214434A1 (en) 2021-07-15
CN118812703A (en) 2024-10-22
CN111601821B (en) 2024-06-14
FR3075200A1 (en) 2019-06-21
WO2019115773A1 (en) 2019-06-20
JP2023134604A (en) 2023-09-27
BR112020012016A2 (en) 2020-11-24
RU2020119543A (en) 2021-12-13

Similar Documents

Publication Publication Date Title
MX2020006013A (en) Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment.
WO2017006052A3 (en) Use of modified fc fragments in immunotherapy
MX2020004129A (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies.
MX2016008782A (en) Fc-region variants with improved protein a-binding.
CO2017004489A2 (en) Modified fgf-21 polypeptides
EA201891495A1 (en) BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
BR112017028550A2 (en) human protein fragment fusion proteins to create ordinary multimerized fc immunoglobulin compositions with enhanced complement ratio
EA201792184A1 (en) ANTIBODIES DIRECTED AGAINST T-CELL IMMUNOGLOBULIN AND MUTIN PROTEIN 3 (TIM-3)
CR20170383A (en) ANTI-CD3 ANTIBODIES, ANTI-CD-123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
PE20180330A1 (en) AFFINITY MATURED AND HUMANIZED ANTIBODIES FOR FCRH5 AND METHODS FOR THEIR USE
BR112016022841A8 (en) IGM, IGA, IGG / IGM OR IGG / IGA ANTIBODY, OR AN ANTIGEN-BINDING FRAGMENT THEREOF, COMPOSITION WHICH COMPRISES IT AND USE THEREOF
ZA202101358B (en) Chimeric antigen receptors against multiple hla-g isoforms
MX2018014456A (en) Antibodies to alpha-synuclein and uses thereof.
UA116479C2 (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
EA201691787A1 (en) ANTAGONISTIC ANTIBODIES DIRECTED AGAINST PEPTIDE CODED BY CALCITONIN GENE AND METHODS OF THEIR APPLICATION
PE20190261A1 (en) ANTIBODIES THAT RECOGNIZE TAU
MX2017011534A (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonsits.
PE20150002A1 (en) ANTI-FCRN ANTIBODIES
AR066411A1 (en) COMPOSITION FOR THE TREATMENT OF A MALIGAN PATHOLOGY, OF AN AUTOIMMUNITY DISEASE OR OF AN INFECTIOUS DISEASE
EA202191231A1 (en) METHODS FOR TREATMENT OF ENDOCRINE OPHTHALMOPATHY USING ANTI-FcRn ANTIBODIES
EA201890340A1 (en) MONOCLONAL ANTIBODY-INHIBITOR OF FACTOR XIIA
MX2022011972A (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same.
MX2020007555A (en) Factor h potentiating antibodies and uses thereof.